# Bo Wang

**Type:** person
**Affiliation:** Xaira Therapeutics (current); University of Toronto / UHN (former)
**X:** @bowang87
**Gmail:** wangbo.yunze@gmail.com

## Description

Computational biologist and AI researcher working at the intersection of machine learning and biology. Co-PI on the LUMI-6 lipid nanoparticle gene editing paper (Cell, Feb 2026). Creator of scGPT.

**Core research focus:**
- AI for drug discovery and target identification
- Single-cell genomics and multi-omics
- Virtual Cell / perturbation biology
- Multi-agent AI systems

**Key thesis:** Virtual Cell ≠ perturbation predictor. Scaling requires causally rich, contextually diverse perturbation data — not just bigger models on the same observational data.

## Key publications

- **scGPT** (Nature Methods 2024) — generative pretrained transformer for single-cell multi-omics; 33M cells; lead author Haotian Cui
- **LUMI-6** (Cell Feb 2026) — brominated lipid achieving 20.3% lung epithelial gene editing in vivo; co-PI with Bowen Li

## Current context (Xaira Therapeutics)

Building causally-rich, contextually-diverse perturbation data infrastructure for Virtual Cells. Focus on data quality and diversity over model scaling.

## Connections

- [../papers/scgpt.md](../papers/scgpt.md) — flagship model
- [../entities/xaira-therapeutics.md](xaira-therapeutics.md) — current employer
- [../concepts/virtual-cell.md](../concepts/virtual-cell.md) — primary research agenda